{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:56:34Z","timestamp":1790546194531,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.heliyon.2024.e33054","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T17:30:59Z","timestamp":1718386259000},"page":"e33054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Liver function tests, CD4+ counts, and viral load among people living with HIV on dolutegravir compared to efavirenz-based cART; a comparative cross-sectional study"],"prefix":"10.1016","volume":"10","author":[{"given":"Enyew Fenta","family":"Mengistu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dr Tabarak","family":"Malik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meseret Derbew","family":"Molla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adane","family":"Adugna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6700-9972","authenticated-orcid":false,"given":"Mohammed","family":"Jemal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.heliyon.2024.e33054_bib1","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.ijrobp.2013.12.032","article-title":"Radiation oncology in Africa: improving access to cancer care on the African continent","volume":"89","author":"Fisher","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"issue":"3","key":"10.1016\/j.heliyon.2024.e33054_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40121-015-0071-0","article-title":"Cost-effectiveness of dolutegravir in HIV-1 treatment-naive and treatment-experienced patients in Canada","volume":"4","author":"Despi\u00e9gel","year":"2015","journal-title":"Infectious diseases and therapy"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33054_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11904-016-0324-x","article-title":"Guidelines for evaluation and management of cognitive disorders in HIV-positive individuals","volume":"13","author":"Underwood","year":"2016","journal-title":"Curr. HIV AIDS Rep."},{"key":"10.1016\/j.heliyon.2024.e33054_bib4","series-title":"Analytical Performance of Four Molecular Platforms Used for HIV-1, HBV and HCV Viral Load Determinations","author":"Simon","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e33054_bib5","series-title":"Preventing and Responding to HIV Drug-Resistance in the African Region: Regional Action Plan 2019-2023","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e33054_bib6","year":"2018"},{"key":"10.1016\/j.heliyon.2024.e33054_bib7","series-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach","year":"2016"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33054_bib8","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/15284336.2018.1511348","article-title":"Sleep and neuropsychological performance in HIV+ subjects on efavirenz-based therapy and response to switch in therapy","volume":"19","author":"Shikuma","year":"2018","journal-title":"HIV Clin. Trials"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33054_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/jia2.25227","article-title":"Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort","volume":"22","author":"Mondi","year":"2019","journal-title":"J. Int. AIDS Soc."},{"key":"10.1016\/j.heliyon.2024.e33054_bib10","series-title":"Policy Brief: Update of Recommendations on First-And Second-Line Antiretroviral Regimens","author":"Organization","year":"2019"},{"key":"10.1016\/j.heliyon.2024.e33054_bib11","series-title":"National Guidelines for Comprehensive HIV Prevention, Care and Treatment","year":"2018"},{"key":"10.1016\/j.heliyon.2024.e33054_bib12","series-title":"52nd Interscience Conference on Antimicrobial Agents and Chemotherapy","article-title":"Dolutegravir (DTG; S\/GSK1349572)+ abacavir\/lamivudine once daily statistically superior to tenofovir\/emtricitabine\/efavirenz: 48-week results\u2014SINGLE (ING114467)","year":"2012"},{"issue":"9936","key":"10.1016\/j.heliyon.2024.e33054_bib13","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e33054_bib14","doi-asserted-by":"crossref","first-page":"ofaa340","DOI":"10.1093\/ofid\/ofaa340","article-title":"Do combination antiretroviral therapy regimens for HIV infection feature diverse T-cell phenotypes and inflammatory profiles?","volume":"7","author":"Tincati","year":"2020","journal-title":"Open Forum Infect. Dis."},{"issue":"19","key":"10.1016\/j.heliyon.2024.e33054_bib15","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir\u2013lamivudine for the treatment of HIV-1 infection","volume":"369","author":"Walmsley","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33054_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1473-3099(11)70290-0","article-title":"Once daily dolutegravir (S\/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial","volume":"12","author":"van Lunzen","year":"2012","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33054_bib17","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0168-8278(01)00291-4","article-title":"Acute liver failure associated with antiretroviral treatment for HIV: a report of six cases","volume":"36","author":"Clark","year":"2002","journal-title":"J. Hepatol."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33054_bib18","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2017-000166","article-title":"Mechanisms of liver disease in patients infected with HIV","volume":"4","author":"Kaspar","year":"2017","journal-title":"BMJ open gastroenterology"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33054_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAD.0b013e3282f0e2fd","article-title":"Antiretroviral drugs and liver injury","volume":"22","author":"Soriano","year":"2008","journal-title":"AIDS"},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33054_bib20","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3851\/IMP2738","article-title":"Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and\/or C","volume":"19","author":"Hurt","year":"2014","journal-title":"Antivir. Ther."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33054_bib21","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0956462417734099","article-title":"Dolutegravir-induced liver injury leading to sub-acute liver failure requiring transplantation: a case report and review of literature","volume":"29","author":"Wang","year":"2018","journal-title":"Int. J. STD AIDS"},{"issue":"6","key":"10.1016\/j.heliyon.2024.e33054_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0179254","article-title":"Safety and tolerability of Elvitegravir\/Cobicistat\/Emtricitabine\/Tenofovir Disoproxil fumarate in a real life setting: data from surveillance cohort long-term toxicity antiretrovirals\/antivirals (SCOLTA) project","volume":"12","author":"Squillace","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.heliyon.2024.e33054_bib23","series-title":"Open Forum Infectious Diseases","article-title":"Abacavir\/dolutegravir\/lamivudine (Triumeq)\u2013Induced liver toxicity in a human immunodeficiency virus\u2013infected patient","year":"2017"},{"key":"10.1016\/j.heliyon.2024.e33054_bib24","series-title":"Livertox: Clinical and Research Information on Drug-Induced Liver Injury","year":"2017"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33054_bib25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1310\/hct1505-199","article-title":"Dolutegravir: clinical and laboratory safety in integrase inhibitor\u2013naive patients","volume":"15","author":"Curtis","year":"2014","journal-title":"HIV Clin. Trials"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33054_bib26","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1186\/s13104-019-4748-4","article-title":"Liver enzyme elevation in patients taking HAART compared with treatment naive controls at Debre Berhan Referral Hospital: a comparative cross-sectional study, Northeast Ethiopia","volume":"12","author":"Tesfa","year":"2019","journal-title":"BMC Res. Notes"},{"key":"10.1016\/j.heliyon.2024.e33054_bib27","series-title":"WHO STEPS Instrument","year":"2012"},{"key":"10.1016\/j.heliyon.2024.e33054_bib28","series-title":"The WHO STEPwise Approach to Noncommunicable Disease Risk Factor Surveillance","article-title":"WHO STEPS instrument (core and expanded)","author":"Organization","year":"2010"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33054_bib29","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2002.30319","article-title":"Hepatotoxicity associated with nevirapine or efavirenz\u2010containing antiretroviral therapy: role of hepatitis C and B infections","volume":"35","author":"Sulkowski","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.heliyon.2024.e33054_bib30","series-title":"Guidelines for Prevention of Mother-To-Child Transmission of HIV in Ethiopia","article-title":"Control office, federal Ministry of Health","author":"Federal","year":"2007"},{"key":"10.1016\/j.heliyon.2024.e33054_bib31","series-title":"Physical Status: the Use of and Interpretation of Anthropometry, Report of a WHO Expert Committee","year":"1995"},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33054_bib32","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/QAI.0000000000001344","article-title":"Brief report: long-term (96-week) efficacy and safety after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in HIV-infected, virologically suppressed adults","volume":"75","author":"Raffi","year":"2017","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33054_bib33","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ajme.2017.03.002","article-title":"Liver enzyme elevations in a cohort of HIV\/AIDS patients on first-line antiretroviral therapy in Namibia: findings and implications","volume":"54","author":"Mataranyika","year":"2018","journal-title":"Alexandria Journal of Medicine"},{"key":"10.1016\/j.heliyon.2024.e33054_bib34","series-title":"Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1.0. Division of AIDS","year":"2004"},{"issue":"9","key":"10.1016\/j.heliyon.2024.e33054_bib35","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1097\/INF.0b013e31817109a4","article-title":"Morbidity and mortality among a cohort of human immunodeficiency virus type 1-infected and uninfected pregnant women and their infants from Malawi, Zambia, and Tanzania","volume":"27","author":"Chilongozi","year":"2008","journal-title":"Pediatr. Infect. Dis. J."},{"key":"10.1016\/j.heliyon.2024.e33054_bib36","series-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach","year":"2016"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33054_bib37","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12879-019-3975-6","article-title":"Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-na\u00efve patients infected with HIV-1: a systematic review and network meta-analysis","volume":"19","author":"Snedecor","year":"2019","journal-title":"BMC Infect. Dis."},{"issue":"8","key":"10.1016\/j.heliyon.2024.e33054_bib38","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1086\/507313","article-title":"Immunogenetics of CD4 lymphocyte count recovery during antiretroviral therapy: an AIDS Clinical Trials Group study","volume":"194","author":"Haas","year":"2006","journal-title":"J. Infect. Dis."},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33054_bib39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1742-6405-8-2","article-title":"Long-term CD4+ lymphocyte response following HAART initiation in a US Military prospective cohort","volume":"8","author":"Lifson","year":"2011","journal-title":"AIDS Res. Ther."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e33054_bib40","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1056\/NEJMoa1904340","article-title":"Dolutegravir-based or low-dose efavirenz\u2013based regimen for the treatment of HIV-1","volume":"381","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33054_bib41","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0232419","article-title":"High acceptability and viral suppression of patients on Dolutegravir-based first-line regimens in pilot sites in Uganda: a mixed-methods prospective cohort study","volume":"15","author":"Nabitaka","year":"2020","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.heliyon.2024.e33054_bib42","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1097\/QAD.0000000000002254","article-title":"Comparative effectiveness of first-line antiretroviral therapy: results from a large real-world cohort after the implementation of Dolutegravir","volume":"33","author":"Meireles","year":"2019","journal-title":"AIDS"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33054_bib43","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1097\/QAD.0b013e3283612419","article-title":"Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study","volume":"27","author":"Stellbrink","year":"2013","journal-title":"AIDS"},{"issue":"5","key":"10.1016\/j.heliyon.2024.e33054_bib44","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1097\/QAI.0000000000000790","article-title":"Brief report: dolutegravir plus abacavir\/lamivudine for the treatment of HIV-1 infection in antiretroviral therapy-naive patients: week 96 and week 144 results from the SINGLE randomized clinical trial","volume":"70","author":"Walmsley","year":"2015","journal-title":"J. Acquir. Immune Defic. Syndr."},{"issue":"9","key":"10.1016\/j.heliyon.2024.e33054_bib45","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0105653","article-title":"48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1\u2013infected patients: a systematic review and network meta-analysis","volume":"9","author":"Patel","year":"2014","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.heliyon.2024.e33054_bib46","doi-asserted-by":"crossref","first-page":"e510","DOI":"10.1016\/S2352-3018(16)30091-1","article-title":"Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis","volume":"3","author":"Kanters","year":"2016","journal-title":"The lancet HIV"},{"issue":"1","key":"10.1016\/j.heliyon.2024.e33054_bib47","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12981-016-0115-x","article-title":"Dolutegravir (DTG, S\/GSK1349572) combined with other ARTs is superior to RAL-or EFV-based regimens for treatment of HIV-1 infection: a meta-analysis of randomized controlled trials","volume":"13","author":"Jiang","year":"2016","journal-title":"AIDS Res. Ther."},{"issue":"Supplement_2","key":"10.1016\/j.heliyon.2024.e33054_bib48","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1086\/381499","article-title":"HIV infection and hepatic enzyme abnormalities: intricacies of the pathogenic mechanisms","volume":"38","author":"Pol","year":"2004","journal-title":"Clin. Infect. Dis."},{"issue":"7","key":"10.1016\/j.heliyon.2024.e33054_bib49","doi-asserted-by":"crossref","first-page":"483","DOI":"10.2165\/00002018-200124070-00001","article-title":"Drug-induced liver disorders","volume":"24","author":"Kaplowitz","year":"2001","journal-title":"Drug Saf."},{"issue":"4","key":"10.1016\/j.heliyon.2024.e33054_bib50","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1086\/649922","article-title":"Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection","volume":"50","author":"Kovari","year":"2010","journal-title":"Clin. Infect. Dis."},{"issue":"2","key":"10.1016\/j.heliyon.2024.e33054_bib51","doi-asserted-by":"crossref","first-page":"53","DOI":"10.18231\/j.pjms.2019.014","article-title":"Correlation of BMI and elevated liver enzyme levels with severity of fatty liver infiltration on ultrasound in Sangrur, Punjab","volume":"9","author":"Jindal","year":"2019","journal-title":"Panacea J. Med. Sci."}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024090856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024090856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T21:05:58Z","timestamp":1790543158000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024090856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S2405844024090856"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33054","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liver function tests, CD4+ counts, and viral load among people living with HIV on dolutegravir compared to efavirenz-based cART; a comparative cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e33054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e33054"}}